Professor of Clinical Rheumatology, King's College London School of Medicine at Guy's, King's and St. Thomas' Hospitals, Academic Department of Rheumatology, Weston Education Centre, 10, Cutcombe Road, London SE5 9PJ, UK.
Expert Rev Pharmacoecon Outcomes Res. 2006 Oct;6(5):495-508. doi: 10.1586/14737167.6.5.495.
Rheumatoid arthritis is a common disease affecting 1% of adults in the UK and western countires. No single outcome measure comprehensively captures the full range of potential outcomes in early rheumatoid arthritis, so a range of measures are needed. This article evaluates the clinical and economic outcomes of early rheumatoid arthritis. These include pain, which is a major concern for patients, fatigue and persisting disease activity. The key therapeutic goal - remission of these clinical features - is achieved by 10-36% of early rheumatoid arthritis patients using currently available treatment. Disability, erosive damage and work disability are other important negative outcomes of early rheumatoid arthritis. Together, they account for its high direct and indirect medical costs. These various outcomes are outlined in this article.
类风湿关节炎是一种常见疾病,在英国和西方国家,1%的成年人受其影响。没有单一的结果测量能够全面捕捉早期类风湿关节炎的所有潜在结果,因此需要多种措施。本文评估了早期类风湿关节炎的临床和经济结果。这些结果包括疼痛(患者的主要关注点)、疲劳和持续的疾病活动。目前可使用的治疗方法使 10-36%的早期类风湿关节炎患者达到了这些临床特征的缓解这一关键治疗目标。残疾、侵蚀性损害和工作残疾是早期类风湿关节炎的其他重要负面结果。这些结果共同导致了其高昂的直接和间接医疗费用。本文概述了这些不同的结果。